Lung cancer treatment depends on the type of cancer, how far it has spread, and what the biopsy and biomarker tests show. Early-stage lung cancer can often be treated with surgery or focused radiation. Locally advanced disease may require a combination of treatments, while metastatic lung cancer is usually treated with medicines such as targeted therapy, immunotherapy, or chemotherapy. The first decision is which treatment fits your situation and in what order it should be given. NCI
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
An abnormal chest scan, a new biopsy report, or a recommendation to start treatment can leave you with very different questions. This page explains how lung cancer is diagnosed, how treatment changes by stage, and which test results can change the plan. If you are seeking lung cancer treatment or a second opinion in Delhi, the checklist below can help you prepare for that discussion.
What are the symptoms and risk factors for lung cancer?
Some lung cancers are found on scans done for another reason. When symptoms occur, they can include a cough that persists or changes, blood in the sputum, shortness of breath, chest pain, hoarseness, or repeated chest infections. Unexplained weight loss, loss of appetite, and persistent fatigue can also occur. These symptoms have several possible causes, so a clinical assessment helps determine which tests are appropriate. Coughing up blood warrants prompt assessment. Heavy bleeding or severe breathlessness requires emergency care. who.int
Smoking is the leading risk factor. Second-hand smoke, outdoor and household air pollution, radon, and workplace exposure to substances such as asbestos, silica, or diesel exhaust can also increase risk. Lung cancer can occur in people who have never smoked. If a symptom persists or a scan shows an abnormality, your smoking history is one part of the assessment. who.int
How do doctors confirm lung cancer and work out its stage?
A CT scan helps identify where the abnormality is and which area may be safest and most informative to sample. A biopsy usually confirms the diagnosis. Depending on the location, tissue may be obtained through bronchoscopy, an endobronchial ultrasound-guided lymph node biopsy, or a CT-guided needle biopsy. Sometimes a lymph node or a suspected site of spread is the best place to sample because it can help establish both the diagnosis and the stage. NCI
The pathology report distinguishes non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). NSCLC includes adenocarcinoma and squamous cell carcinoma. The distinction matters because the two main types follow different treatment pathways. Depending on the findings, staging may include PET-CT, brain MRI, or sampling of lymph nodes in the chest. The team may also assess lung function and overall fitness if surgery or chest radiation is being considered. NCI
How is early-stage lung cancer treated?
For many people with stage I or II non-small cell lung cancer, treatment is planned with the aim of cure. Surgery is often considered when the cancer can be removed and the patient has enough lung and heart reserve for the operation. For selected patients with early-stage disease who cannot undergo surgery, stereotactic body radiotherapy (SBRT) can deliver focused radiation to the tumour. NCI
The next question is whether treatment around surgery could reduce the risk of recurrence. Some patients benefit from chemotherapy, sometimes combined with immunotherapy, before surgery. Others may be advised to have chemotherapy, targeted therapy, or immunotherapy after surgery. The decision depends on factors such as tumour size, lymph node involvement, pathology, and relevant biomarkers. If surgery is being considered, ask whether any biomarker result is needed before the team chooses the treatment sequence. NCI
How is locally advanced lung cancer treated?
Stage III non-small cell lung cancer covers several patterns of disease within the chest. The first question is whether the cancer can be removed safely and completely. A thoracic surgeon, radiation oncologist, and medical oncologist review the scans and lymph node findings together. In selected cases, surgery can form part of a treatment plan that also includes systemic therapy. NCI
When surgery is unsuitable, chemotherapy and radiation given together are often considered for patients fit enough to receive both. For some patients, giving them one after the other is more appropriate. If the cancer has not progressed after chemoradiation, additional treatment may be considered. This could include immunotherapy for eligible patients or a targeted drug for certain EGFR-mutated cancers. Stage III disease can still be treated with the aim of cure, and the most suitable approach depends on the extent of disease, tumour biology, and overall health. NCI
How is metastatic lung cancer treated?
In stage IV non-small cell lung cancer, medicines that act throughout the body are usually the main treatment. The goals are to control the cancer, relieve symptoms, preserve day-to-day function, and help patients live longer where possible. Radiation or another local treatment may also be used for specific problems, such as a painful bone lesion or a brain metastasis. NCI
| Treatment decision | What guides it |
|---|---|
| Targeted therapy | If testing finds a cancer-driving alteration with a suitable treatment, targeted therapy may be the preferred first treatment. Examples include certain EGFR mutations and ALK or ROS1rearrangements. The exact alteration matters because different changes in the same gene can lead to different choices. |
| Immunotherapy | When there is no alteration that calls for a targeted drug first, PD-L1, the cancer subtype, and overall health help guide whether immunotherapy is used alone or with chemotherapy. A high PD-L1 result is interpreted alongside the molecular findings. |
| Biomarker-driven therapy | This is the process of using tumour test results to choose and sequence treatment. Broad molecular profiling, often by next-generation sequencing (NGS), can look for several alterations from one sample. PD-L1 is usually assessed with a separate test. |
| Chemotherapy and supportive care | Chemotherapy remains part of many treatment plans. Supportive and palliative care can start alongside cancer treatment to help with symptoms such as breathlessness, pain, fatigue, or poor appetite. |
If tissue is limited or difficult to obtain, a liquid biopsy may help identify some actionable alterations. A negative blood result can miss an alteration, so tissue testing may still be needed when feasible. When a patient is clinically stable, it is often worth reviewing the relevant biomarker results before committing to first-line therapy. If symptoms require urgent treatment, the team can discuss what needs to start while testing is underway. ASCO Publications
How targeted therapies are selected · PD-L1 testing before immunotherapy · Molecular profiling and biomarker-driven therapy in lung cancer
Is small cell lung cancer treated differently?
Yes. Small cell lung cancer is commonly grouped into limited-stage and extensive-stage disease. Limited-stage disease is often treated with chemotherapy and chest radiation, with additional immunotherapy considered for eligible patients after chemoradiation. Extensive-stage disease is usually treated with chemotherapy and, for suitable patients, immunotherapy. Radiation may be used in selected situations. The pathology distinction between small cell and non-small cell lung cancer therefore changes the treatment plan from the outset. NCI
What I look for clinically before recommending a treatment plan
I start by checking whether the biopsy and scans answer the questions that determine the first treatment. Has the pathology confirmed the subtype? Would sampling a chest lymph node change the recommendation about surgery? Is there enough tissue for the tests that matter? If a report says “EGFR positive” or “PD-L1 high,” I review the exact finding and how it applies to this stage of disease. I also ask what matters most to the patient, including symptom relief, time at home, treatment visits, and costs. For someone considering treatment in Delhi while living elsewhere, we can discuss which parts of care need to be coordinated in person and which can be managed closer to home.
How the next step is decided
| If this is the situation | Then the next discussion is about |
|---|---|
| A scan is suspicious and there is no tissue diagnosis | Where to biopsy and whether that sample can also help establish the stage |
| The cancer appears confined and potentially removable | Surgery, lung fitness, and whether treatment before or after surgery may help |
| The cancer involves lymph nodes in the chest | Whether surgery has a role or chemoradiation should lead the plan |
| The cancer has spread and biomarker results are pending | Which decisions can wait for the results and whether any symptoms need treatment now |
| The cancer grows during or after treatment | Whether repeat imaging, a new biopsy, or updated molecular testing could change the next treatment |
What to bring for a lung cancer consultation in Delhi
- Biopsy report, including any immunohistochemistry results. If available, bring details for obtaining the slides or tissue block.
- CT, PET-CT, and MRI reports, along with the actual images on disc or through an access link.
- Complete biomarker reports, including PD-L1, tissue NGS, or liquid biopsy results.
- Details and dates of any surgery, chemotherapy, radiation, targeted therapy, or immunotherapy already received.
- A current medication list and information about heart or lung disease, autoimmune conditions, and other major illnesses.
- The proposed treatment plan, if you have one, and the questions you want answered before deciding.
Structured cancer second opinion · Delhi consultation locations and contact details
Frequently asked questions
Can lung cancer occur in someone who has never smoked?
Yes. A person who has never smoked can develop lung cancer. Persistent symptoms or a suspicious scan deserve evaluation based on the clinical findings. who.int
Can stage III lung cancer be treated with the aim of cure?
Yes, in many cases. The treatment may involve surgery as part of a combined plan or definitive chemoradiation. The pattern of lymph node involvement and the patient’s fitness help guide that choice. NCI
Does a high PD-L1 result mean I should start immunotherapy?
PD-L1 is one part of the decision. In metastatic NSCLC, the team also checks for actionable alterations, such as certain EGFR mutations or an ALK rearrangement, that can change which treatment should come first. ASCO Publications
Should I wait for my molecular test results before starting treatment?
Ask whether the pending result could change the first treatment and whether it is safe to wait. For a clinically stable patient with metastatic NSCLC, an actionable result can materially change the plan. If symptoms are worsening, the team may need to act while results are pending. ASCO Publications
When can a lung cancer second opinion help?
A review can help when there is uncertainty about surgery, when a biomarker report is difficult to interpret, or when cancer has progressed on treatment. Sharing the original images, pathology, and proposed plan helps focus the discussion on the decision you need to make.
Before starting treatment, ask your team to explain the aim of treatment, which results support the proposed plan, and what finding would change it. Those three answers can help you understand the options and discuss them with your family.
This page is for general education. Individual treatment decisions require review of your reports, symptoms, and overall health by your treating team.
Clinical references
- World Health Organization. Lung cancer fact sheet
- National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ)
- National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ)
- American Society of Clinical Oncology. Stage IV NSCLC living guidelines with driver alterations and without driver alterations